Kornimate/medical-research-clean huggingface dataset:
detection of adenomas in screening colonoscopy

Conditions: Adenoma Colon

Summary: the endocuff study aims to show an increase of the number of detected adenomas in screening colonoscopies when a endocuff vision (arc medical design ldt leeds england) is used.

endocuff is a relatively new device which is intended to be attached to the end of the colonoscope. several minor studies have shown that the use of endocuff probably increases the number of detected polyps in colonoscopy. endocuff is made of soft plastic and has been designed to give an optimal view of the entire colon. it gently averts and flattens folds in order to see small polyps "hiding" in the space behind colonic folds. the purpose of this study is to investigate into the effect of the endocuff in screening colonoscopy compared with screening colonoscopy performed without endocuff. the device has been used during several years yet an effect on the number of polyps detected during screenings colonoscopy has not been shown. this studies main hypothesis is that the use of endocuff in screenings colonoscopy will increase the adenoma detection rate in these patients, with a potential to reduce interval cancer. this study is a randomized controlled trial with 900 patients.

Eligibility criteria:
inclusion criteria: * all citizens participating in the national bowel screening program exclusion criteria: * persons who are disabled and who do not understand the danish language * persons treated with marcoumar, marevan, eliquis, pradaxa e.g. and who are not eligible to polyp resection * persons who due to diseases of the eyes or heart are not allowed to receive buscopan. * persons with active colitis/diverticulitis, colon stenosis e.g. due to cancer, where a complete colonoscopy is not possible to achieve

Keywords: adenoma detection rate screening colonoscopy
complications in lower body lifts

Conditions: Surplus Skin After Massive Weight Loss

Summary: a prospective study on 50 consecutive patients who are going to have a lower body lift procedure is performed. measures include comorbidities and complications. risk factors assessed including patient age, gender, highest lifetime body mass index (bmi) (bmi max), current bmi, excess weight loss (ewl), type of weight loss and nicotine consumption.


Eligibility criteria:
inclusion criteria: * after massive weight loss * age \> 18 years and \< 65 years * excess weight loss \> 66% * current body mass index \< 35 * stable weight after weight loss for at least 12 months exclusion criteria: * insulin dependent diabetes mellitus

Keywords: lower body lift body contouring surgery massive weight loss
an observational study of avastin in first line in elderly patients with metastatic colorectal cancer (cassiopee)

Conditions: Colorectal Cancer

Summary: this multicenter, prospective, observational study will evaluate the efficacy and safety of avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer. data will be collected from eligible patients for24 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 75 years of age * metastatic colorectal cancer * initiating avastin first-line therapy in combination with chemotherapy exclusion criteria: * previous avastin therapy * patient participating in a clinical study evaluating a cytotoxic anti-cancer therapy and/or an investigational new drug
asa- and clopidogrel-responsiveness in patients with peripheral arterial occlusive disease and interventional procedures

Conditions: Peripheral Arterial Occlusive Disease

Summary: the purpose of the study is to determine the response to aspirin (asa) and clopidogrel in patients with peripheral arterial occlusive disease (paod) requiring interventional procedures and to investigate if patients with "resistance" to asa or clopidogrel have an unfavourable outcome during long-term follow-up


Eligibility criteria:
inclusion criteria: * paod patients * age 18-85 years * need for a catheter interventional procedure * antithrombotic therapy with aspirin or clopidogrel exclusion criteria: * comedication additionally compromising platelet function * known bleeding disorder * life expectancy \< 6 months

Keywords: peripheral arterial occlusive disease aspirin clopidogrel resistance catheter interventional procedure asa and clopidogrel resistance
coronary artery calcium, exercise tests, and chd outcome

Conditions: Cardiovascular Diseases; Coronary Disease; Cerebrovascular Disorders; Heart Diseases; Cerebrovascular Accident

Summary: to investigate coronary artery calcium (cac), detected by electron beam computed tomography (ebct), as a predictor of coronary heart disease (chd) mortality and morbidity, stroke, and all-cause mortality in a historical cohort epidemiological study.

background: dramatic advances in medical and interventional treatment of clinically overt chd have contributed substantially, perhaps predominately, to the decline over the past three decades in chd mortality that has occurred despite relatively unchanged rates of myocardial infarction. by analogy, it is attractive to assume that substantial benefit could also be given to individuals with significant but asymptomatic coronary artery disease if only they could be accurately diagnosed. in this context, research to determine whether or not a non-invasive method like ebct has sufficient independent predictive value for chd events to play a useful role in this process has potentially considerable clinical and public health importance. design narrative: follow-up of the 5,400 women and 12,600 men will be for an average of about 2.75 years with approximately 15,000 woman-years and 35,000 man-years of observations being available for analyses by june 30, 2000. an important strength of the study is the self-reported key health variables at baseline for all study participants. in addition, objective measures of blood pressure, total cholesterol, hdl- cholesterol, triglyceride, plasma glucose, resting and exercise electrocardiograms (ecg), maximal health rates, cardiorespiratory fitness, and other clinical and biochemical measurements are available for about half of the participants. cac by ebct has been associated with prevalent chd and with incident chd in recent small prospective studies. however, it is unclear whether cac is predictive of mi or chd deaths, because currently available studies had few individuals with evidence of hard cvd endpoints. the large cohort with cac measurements provides the power to investigate an association between cac and chd morbidity, stroke, and all- cause mortality in terms of thresholds or dose-response effects. exercise test results and measures of conventional chd risk factors, including several health behaviors and biochemical markers, are available for about 50 percent of the participants. this will allow evaluation of the separate and independent predictive value of cac and exercise test results and the combination of these two exposures in relation to study outcomes. furthermore, cac scores, exercise test results, and the presence of conventional risk factors will be used together to identify participants at the highest risk of developing chd outcomes.

Eligibility criteria:
no eligibility criteria
seroprevalence and vaccination rate of hepatitis b virus and varicella-zoster virus among medical students under immunizing program

Conditions: Healthy; Healthy Adult

Summary: this study is a cross-sectional study. the study aims to determine the levels of immunity against hepatitis b virus and varicella-zoster virus in medical students.

this study is a cross-sectional study aimed at determining the levels of immunity against the hepatitis b virus and varicella virus in medical students. additionally, it aims to compare the rate of increase in immunity levels before and after receiving the hepatitis b and varicella-zoster vaccines in medical students. medical students aged 18 years or older are included in the study.

Eligibility criteria:
inclusion criteria: * medical students * age 18 years or older exclusion criteria: * known cases of hepatitis b virus infection * known cases of varicella-zoster virus infection

Keywords: hepatitis b virus varicella-zoster virus vaccination immunizing program medical students
park-fit. treadmill vs cycling in parkinson´s disease. definition of the most effective model in gait reeducation

Conditions: Parkinson Disease

Summary: park-fit treadmill vs cycling in parkinson´s disease rehabilitation. non-pharmacological clinical trial for the definition of the most effective model in gait reeducation.

treadmill vs cycling in parkinson´s disease rehabilitation. non-pharmacological clinical trial for the definition of the most effective model in gait reeducation.

Eligibility criteria:
inclusion criteria: * patient is diagnosed with idiopathic parkinson's disease according to criteria from the united kingdom parkinson's disease society brain bank (uk-pdsbb) * h\&y less than or equal to 2 * stable drug treatment in the six weeks prior to the start of training and during the study. * signature of informed consent. exclusion criteria: * diagnosis of other neuro-degenerative disease * cardiovascular disease or other systemic condition that contraindicates the moderate physical exercise * need for ambulation support * frequent freezing of gait events. * mni- mental state examination (mmse) \<26
malaria active epidemiology and treatment study

Conditions: Malaria

Summary: an observational cohort and malaria treatment study in cambodia.

this is an active observational cohort study of malaria epidemiology with a nested two arm, randomized, open label treatment study comparing the efficacy, safety, tolerability and pharmacokinetics of a two versus three day course of dihydroartemisinin-piperaquine (dp) for those developing uncomplicated malaria. at the conclusion of the cohort study, a subset of volunteers with documented exposure to plasmodium vivax during the study will be treated with primaquine as presumptive anti-relapse therapy directed against the exoerythrocytic malaria stages of p. vivax, and followed passively for an additional 6 months.

Eligibility criteria:
inclusion criteria: 1. otherwise healthy volunteer, 18-65 years of age, eligible for care at an rcaf facility, and at risk for contracting malaria 2. able to provide informed consent 3. likely to reside in endemic area for the duration of the study 4. available for follow-up for anticipated study duration, and agrees to participate for the duration of the study 5. authorized by local commander to participate in the study if on active duty exclusion criteria: 1. history of allergic reaction or contraindication to dha or piperaquine 2. significant acute comorbidity requiring urgent medical intervention 3. pregnant or lactating female, or a female of childbearing age who does not agree to use a highly effective method of birth control during the study 4. clinically significant abnormal ekg, including a qtc interval \> 500 ms. 5. judged by the investigator to be otherwise unsuitable for study participation

Keywords: plasmodium falciparum, plasmodium vivax
efficacy of thrombosuction in primary percutaneous coronary intervention of acute myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the present study was designed to investigate whether the thrombus aspiration using export aspiration catheter (medtronic corporation, california, usa) during primary percutaneous coronary intervention (pci) in acute myocardial infarction improve clinical outcomes.

primary percutaneous coronary intervention (pci) is the preferred strategy for immediate revascularization in patients with acute st-elevation myocardial infarction (stemi). a meta-analysis of trials comparing primary pci to fibrinolytic therapy showed a mortality benefit to the invasive approach. however, although timi iii flow is achieved in the culprit epicardial vessel in the majority of patients, lack of tissue-level reperfusion is observed in approximately 30% of patients as manifested by persistence of chest pain and st-segment elevation. many strategies have tried to overcome this problem, from mechanical thrombectomy and distal protection devices to myocardial preserving agents. the purpose of present study is to investigate the efficacy of the thrombus aspiration using export aspiration catheter (medtronic corporation, california, usa) during primary pci in acute myocardial infarction.

Eligibility criteria:
inclusion criteria: * patients with first st-elevation myocardial infarction who undergo primary pci within 12 hours after symptom onset * patients who are eligible for pci exclusion criteria * history of bleeding diathesis or coagulopathy * pregnant * known hypersensitivity or contra-indication to contrast agent * left main disease * in-stent restenosis lesion * graft vessels lesion * chronic total occlusion lesion * renal dysfunction, creatinine more than 2.0 mg/dl * contraindication to aspirin, clopidogrel or cilostazol * prior pci or bypass surgery * old myocardial infarction

Keywords: thrombus aspiration percutaneous coronary intervention
the multidisciplinary, multimodality, but minimalist approach to transfemoral transcatheter aortic valve replacement

Conditions: Aortic Valve Stenosis

Summary: the primary objective of this study is to determine the efficacy, safety and feasibility of next day discharge home in patients undergoing balloon-expandable transfemoral tavr utilizing the vancouver 3m clinical pathway in low, medium, and high volume north american centres.


Eligibility criteria:
inclusion criteria: patients with severe symptomatic aortic stenosis undergoing elective transfemoral tavr with a balloon expandable transcatheter heart valve 1. considered at increased surgical risk by the multidisciplinary heart team. 2. informed written consent exclusion criteria: 1. non -cardiovascular co-morbidity reducing life expectancy to \< 3 years 2. any factor precluding 1 year follow-up 3. inadequate ct image acquisition to perform area-based annular ct sizing, exclude adverse root features, and determine a coaxial valve deployment angle (ct is not required for valve-in-valve procedures) 4. predicted inability to perform uncomplicated percutaneous vascular access and closure 5. iliofemoral diameter \< 6 mm for sapien xt or \<5.5 mm for sapien 3 (measured at or above the mid-femoral head) 6. inpatient (unless clinically stable, mobilizing at baseline, and primarily in hospital for logistical reasons. 7. significant communication barrier(s) that interfere with ability to follow peri-procedural and discharge instructions 8. mmse \ 7 seconds (unless chronic mobility impairment not affecting ability to perform adls), and adl \< 6/6 9. insufficient social support to facilitate next day discharge 10. airway unfavourable for emergent intubation 11. inability to lay supine without conscious sedation or general anesthetic 12. not receiving a balloon expandable transcatheter heart valve

Keywords: transcatheter aortic valve replacement
htx-011 in spinal surgery

Conditions: Post-Operative Pain; Lumbar Laminectomy

Summary: this is a phase 2, multicenter study in subjects undergoing an open lumbar decompression surgery.


Eligibility criteria:
inclusion criteria: * is scheduled to undergo an open 1-3 level lumbar decompression surgery with or without fixation under general anesthesia. * females are eligible only if not pregnant, not lactating, not planning to become pregnant during the study. exclusion criteria: * has a contraindication of a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications. * has a history of severe allergic reaction due to aspirin or other nsaids, or known history of severe gastrointestinal adverse reactions associated with nsaid use. * has functioning intrathecal drug pump or spinal cord stimulator. * opioid use for most days within the last 3 months. * has initiated treatment with selective serotonin reuptake inhibitors (ssris), selective norepinephrine reuptake inhibitors (snris), gabapentin, pregabalin, or duloxetine within 1 month prior to the scheduled surgery. * received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives. * has a history of clinically significant cardiac abnormality, coronary artery bypass graft surgery within 12 months, or suspected coagulopathy or uncontrolled anticoagulation. * has impaired balance and is at risk of falling. * is currently undergoing treatment for hepatitis b, hepatitis c, or hiv. * has undergone 3 or more surgeries within 12 months. * has a known history of glucose-6-phosphate dehydrogenase deficiency. * has history of liver cirrhosis, having an aspartate aminotransferase \>3 × the upper limit of normal (uln), or having an alanine aminotransferase \>3 × uln.

Keywords: postoperative pain local anesthetic lumbar laminectomy lumbar decompression
a safety and efficacy study of dexamethasone versus laser photocoagulation in participants with diabetic macular edema

Conditions: Macular Edema

Summary: this study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (dme).


Eligibility criteria:
inclusion criteria: * diagnosis of diabetes mellitus (type 1 or type 2) * presence of macular edema exclusion criteria: * anticipated need for ocular surgery in the study eye during the study * laser photocoagulation in the study eye within 3 months * cataract surgery within 3 months
study to assess safety and efficacy of ticagrelor (azd6140) versus clopidogrel in asian/japanese patients with non-st or st elevation acute coronary syndromes (acs)

Conditions: Acute Coronary Syndrome; Percutaneous Coronary Intervention

Summary: the purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of ticagrelor (azd6140) compared with clopidogrel, both given on top of low dose aspirin, in asian/japanese patients with acute coronary syndrome and a planned percutaneous coronary intervention (pci).


Eligibility criteria:
inclusion criteria: * provision of signed informed consent * index event of non-st or st segment elevation acs exclusion criteria: * index event is an acute complication of percutaneous coronary intervention * patient has undergone percutaneous coronary intervention (pci) after the index event before the first dose of study treatment * oral anticoagulation therapy that cannot be stopped * the conditions associated with increased risk of bradycardiac events

Keywords: acute coronary syndrome coronary disease coronary artery disease
iron balance study of dfo and gt56-252 in patients with transfusional iron overload secondary to beta-thalassemia

Conditions: Beta-Thalassemia

Summary: a clinical trial designed to compare the safety and iron excretion properties of desferoxamine (dfo) and deferitrin (gt56-252), an experimental oral iron chelator.


Eligibility criteria:
inclusion criteria: * beta-thalassemia patients, 18 years of age or older, currently undergoing chronic blood transfusion therapy and iron chelation therapy who weigh more than 40 kg. * no clinically significant findings on physical exam, medical history, or screening laboratories. * serum ferritin greater than 500 ng/ml, serum creatine creatinine within the normal range and platelet count greater than 100,000/mm3. * willing and able to discontinue dfo or l1 for the period of study. * woman of child-bearing potential must have a negative serum pregnancy test at screening and use a medically acceptable form of birth control during the study and for 1 month afterward. male patients must also use barrier contraceptives during the study and for 1 month afterward. * have a level of understanding and willingness to cooperate with the confinement and all procedures. able to provide voluntary signed/dated written informed consent. exclusion criteria: * serious medical condition unrelated to beta-thalassemia. * participation in a previous investigational drug study within 30 days preceding screening. * patients with a known allergy to dfo that prevents chronic administration.

Keywords: beta thalassemia
brief behavioral activation intervention for depressed asthma and urticaria patients

Conditions: Depression; Asthma; Urticaria

Summary: depression and other unhealthy behaviors, such as not taking medication as prescribed and not attending doctor visits have been suggested to increase the worsening of allergic diseases (e.g. asthma, urticaria). we intend to determine whether a one-session behavioral intervention is effective in helping with depression and controlling disease symptoms. we will measure this using pre- and post-intervention surveys.

the purpose of this research study is to investigate whether a one-session behavioral activation intervention for depression can successfully reduce depression and improve asthma or urticaria disease-relevant outcomes (medication adherence, doctor's visits, substance abuse) in clinical patients with asthma or urticaria who report heightened levels of depression and are seen in the ummc allergy clinic.

Eligibility criteria:
inclusion criteria: * potential participants should be between the ages 18 and 64, seen in the ummc allergy clinic with either asthma or urticaria and who report symptoms of depression in the previous 2 weeks. exclusion criteria: * potential participants younger than 18 and older than 64 or who do not speak english or cannot comprehend the consent form or women who are pregnant are excluded.

Keywords: depression asthma urticaria
efficacy study of tln-4601 in patients with recurring glioblastoma multiforme

Conditions: Glioblastoma Multiforme

Summary: the objective of this study is to assess the efficacy and safety of tln-4601 used to treat patients with glioblastoma multiforme(gbm) that recur/progress after receiving first line systemic therapy post surgery/radiotherapy.


Eligibility criteria:
inclusion criteria: * histologically confirmed glioblastoma multiforme (gbm) * prior treatment with radiation and one first line systemic therapy (including temozolomide or other chemotherapy, immunotherapy, targeted therapy or combination therapies), followed by measurable and unequivocal evidence of tumor progression or recurrence * age ≥ 18 years * ecog ≤ 2 * normal organ and marrow function as defined below: * leukocytes ≥3 x 109/l * absolute neutrophil count ≥1.5 x 109/l * platelets ≥100 x 109/l * hemoglobin ≥90 g/l * total bilirubin ≤2.5 x institutional upper limit of normal * ast(sgot)/alt(sgpt) ≤2.5 x institutional upper limit of normal * creatinine ≤1.0 x institutional upper limit of normal exclusion criteria: * patients with a life expectancy \< 12 weeks * patients with a documented history of hiv, active hepatitis b or c infections * female patients who are pregnant or lactating * patients in whom a proper central line (portacath-like device) cannot be established * patients with a known hypersensitivity to farnesylated dibenzodiazepinone or polysorbate 80 * patients with uncontrolled hypotension * patients with concomitant therapy of therapeutic coumadin

Keywords: glioblastoma multiforme (gbm) phase ii brain cancer